<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Differentiated thyroid cancer refractory to standard treatment: Systemic therapy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Differentiated thyroid cancer refractory to standard treatment: Systemic therapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Differentiated thyroid cancer refractory to standard treatment: Systemic therapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven I Sherman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew G Gianoukakis, MD, FACE</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Treatment of most patients with differentiated thyroid cancer (DTC; both papillary and follicular histologies) includes surgery, thyroid hormone therapy, and selective use of radioiodine. When metastatic disease occurs, radioiodine can be curative in a minority of patients, and thyroid-stimulating hormone (TSH)-suppressive thyroid hormone therapy can help to slow the pace of the disease. In addition, external radiotherapy may be useful in some patients. (See  <a class="medical medical_review" href="/z/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management"</a> and  <a class="medical medical_review" href="/z/d/html/7818.html" rel="external">"Differentiated thyroid cancer: Radioiodine treatment"</a> and  <a class="medical medical_review" href="/z/d/html/2192.html" rel="external">"Differentiated thyroid cancer: External beam radiotherapy"</a>.)</p><p>However, for those patients with metastatic DTC that progresses despite systemic treatment such as radioiodine and TSH-suppressive thyroid hormone therapy, or focal treatments such as surgery and external beam radiotherapy (EBRT), treatment options have historically been limited. New approaches based upon application of targeted therapies have emerged as effective alternatives for progressive disease.</p><p>Systemic targeted therapy for advanced DTC that progresses despite radioiodine and TSH-suppressive thyroid hormone will be reviewed here. Therapies for medullary and anaplastic thyroid cancers are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">"Medullary thyroid cancer: Systemic therapy and immunotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/2189.html" rel="external">"Anaplastic thyroid cancer"</a>.)</p><p class="headingAnchor" id="H12612780"><span class="h1">PATIENT SELECTION FOR SYSTEMIC THERAPY</span><span class="headingEndMark"> — </span>Systemic therapy may be used in patients at significant risk for morbidity or mortality due to progressive metastatic disease in whom benefit of therapy is likely to reasonably outweigh the risks and cost. The rate of disease progression is variable in patients with metastatic differentiated thyroid cancer (DTC), and therefore the pace of disease progression is an important factor in the decision to treat with systemic therapy.</p><p>The ideal time to initiate systemic therapy remains unclear. A prospective noninterventional study in patients with progressive, <strong>asymptomatic</strong>, radioiodine refractory DTC attempted to compare outcomes in patients who were treated with a multikinase inhibitor at study entry with those who continued active surveillance [<a href="#rid1">1</a>]. However, the slow accrual of events in both groups prevented the planned analysis.</p><p>Our approach to identifying patients for systemic therapy is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients treated with systemic agents should have a baseline performance status sufficiently functional to tolerate these interventions, such as being ambulatory at least 50 percent of the day (Eastern Cooperative Oncology Group [ECOG] performance status 2 or better). The most commonly used systemic therapies, kinase inhibitors, are associated with adverse effects that may significantly impact quality of life. (See <a class="local">'Side effects shared by oral kinase inhibitors inhibiting VEGFR'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should be evaluated with comprehensive computed tomography (CT) and/or magnetic resonance imaging (MRI) to establish the extent of disease and disease progression. Prior to therapy or in any patient with suspicious central nervous system symptoms, imaging of the brain should be performed to rule out intracranial metastases that might require other forms of intervention first, such as surgery or radiation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with asymptomatic metastatic tumors generally less than 1 to 2 cm in diameter and growing in diameter less than 20 percent per year can usually be <strong>monitored</strong> for disease progression (active surveillance). In this group of patients, known sites of metastatic disease should be imaged by CT or MRI every six months, and potential new sites of disease should be imaged every 12 to 24 months. We continue treatment with TSH suppression (with TSH levels as low as the patient can tolerate, though not necessarily undetectable [<a href="#rid2">2</a>]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with unresponsive metastatic tumors of at least 1 to 2 cm in diameter and growing by at least 20 percent per year, or patients with symptoms related to multiple metastatic foci that cannot be alleviated with localized treatment such as surgery or external beam radiotherapy (EBRT) are candidates for <strong>systemic therapy</strong>. Emphasis should be placed on overall tumor burden or individual lesion location, growth trajectory, and potential for morbidity if disease is allowed to progress further.</p><p></p><p class="headingAnchor" id="H2127118077"><span class="h1">INITIAL SYSTEMIC THERAPY</span><span class="headingEndMark"> — </span>The following approach is based upon clinical experience and data from placebo-controlled randomized trials (<a class="graphic graphic_algorithm graphicRef130436" href="/z/d/graphic/130436.html" rel="external">algorithm 1</a>). Our approach is largely consistent with the American Thyroid Association (ATA) and National Comprehensive Cancer Network (NCCN) guidelines, with modifications based upon subsequent research findings [<a href="#rid3">3-5</a>].</p><p class="headingAnchor" id="H2676915939"><span class="h2">General principles</span></p><p class="bulletIndent1"><span class="glyph">●</span>We prefer to administer systemic treatment in the context of a clinical trial. (Active clinical trials can be identified at: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fterm%3Dthyroid%2Bcancer%26recr%3DOpen&amp;token=RX0MbOaTp1kS6NCectJwzk2uEWpEWZoQPsdoKB16yZ3qpAUA9NDUrOsNaQ%2BcORTizx9RRRP%2B0nifSJG7uNrXvkV%2BLlyGRF5xkgeizFPzAO8%3D&amp;TOPIC_ID=2191" target="_blank">ClinicalTrials.gov</a>.) Increasingly, the selection of a specific systemic agent is dictated by the presence of specific gene mutations or signaling pathway abnormalities that are the targets of approved or investigational therapies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who are unable to participate in clinical trials, first-line treatment options include oral kinase inhibitors that target either angiogenesis or oncogenic signaling pathways. The choice of initial kinase inhibitor depends on the result of somatic mutation testing, if available. (See <a class="local">'Targetable mutation not identified'</a> below and <a class="local">'Targetable mutation identified'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients whose disease burden, rate of tumor growth, or symptoms necessitate consideration of systemic therapy options, somatic mutation testing can be performed to identify oncogenic kinase abnormalities that might suggest specific treatment options that cannot be administered in the absence of mutational data (eg, gene rearrangements in <em>NTRK, ALK</em>, or <em>RET,</em> or point mutations in <em>BRAF</em>). Given the high cost of such testing and lack of coverage by some insurance providers, this option may not be realistic for some patients, even if the lack of testing limits therapeutic options. Options for reduced cost mutation testing may be available through pharmaceutical companies marketing such targeted drugs.</p><p></p><p>In most tumors, kinases function as key signaling intermediates that stimulate tumor proliferation, angiogenesis, invasion, metastasis, and avoidance of apoptosis, affecting both the cancer cells as well as the other components of the tumor microenvironment, such as the vascular endothelium. Antiangiogenic multikinase inhibitors (aaMKIs) can improve progression-free survival. However, kinase inhibitors are disease-modifying agents, usually tumoristatic rather than tumoricidal, and only one published study has demonstrated that one of these new agents improved overall survival in a specific prespecified subgroup of patients with thyroid cancer [<a href="#rid6">6</a>].</p><p>Conventional cytotoxic agents are rarely used for the treatment of patients with progressive symptomatic differentiated thyroid cancer (DTC) that is unresponsive or not amenable to surgery, radioiodine therapy, or external radiotherapy; complete remission is rare, and long-term responses are uncommon [<a href="#rid7">7,8</a>]. (See <a class="local">'Therapies infrequently used'</a> below.)</p><p>In the studies described below, the definitions of tumor response are based upon the now-standard Response Evaluation Criteria in Solid Tumors (RECIST) (<a class="graphic graphic_table graphicRef74693" href="/z/d/graphic/74693.html" rel="external">table 1</a>) [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H229112358"><span class="h2">Targetable mutation not identified</span></p><p class="headingAnchor" id="H1528212011"><span class="h3">Multitargeted kinase inhibitor</span><span class="headingEndMark"> — </span>In the absence of a specific targetable mutation (eg, <em>NTRK</em>, <em>ALK</em>, <em>RET, </em>or <em>BRAF</em>), or if mutation profiling results are not available, we suggest <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> as first choice among oral aaMKIs (<a class="graphic graphic_algorithm graphicRef130436" href="/z/d/graphic/130436.html" rel="external">algorithm 1</a>). <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">Sorafenib</a> is an alternative option.</p><p>As head-to-head comparisons among the various aaMKIs have not been performed and the various trials often have recruited patients with differing eligibility criteria, the selection of which agent to use for initial treatment should prioritize both better study design (such as randomized trials) and a somewhat subjective ranking of drug efficacy and adverse events. Randomized trial evidence supports benefit with <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> [<a href="#rid10">10,11</a>], <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> [<a href="#rid12">12</a>], and <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a> [<a href="#rid13">13</a>], but nonrandomized trials have also indicated efficacy with <a class="drug drug_general" data-topicid="9524" href="/z/d/drug information/9524.html" rel="external">pazopanib</a> [<a href="#rid14">14</a>], <a class="drug drug_general" data-topicid="10305" href="/z/d/drug information/10305.html" rel="external">sunitinib</a> [<a href="#rid15">15-17</a>], and other aaMKIs. We prefer lenvatinib as first-line therapy because of the high rate of efficacy and evidence of improved survival in older patients, although it has not been directly compared with other aaMKIs in randomized trials.</p><p>Many of the aaMKIs partially inhibit multiple tyrosine kinases (ie, they are multitargeted) at nanomolar concentrations in vitro and often affect multiple signaling pathways. The primary target for all of these effective tyrosine kinase inhibitors is angiogenic signaling in the tumor microenvironment, particularly the vascular endothelial growth factor receptor (VEGFR) family. Although it may take several months before maximum radiographic response is achieved, targeting angiogenesis (and specifically VEGFR signaling pathways) has produced valuable clinical responses and prolonged progression-free survival in randomized trials for metastatic DTC. In phase III trials, median progression-free survival times of 11 to 18 months are reported, with partial responses in up to 63 percent of patients (though complete responses are rare) [<a href="#rid11">11,12</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lenvatinib</strong> – <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">Lenvatinib</a> is an inhibitor of VEGFR, and to a lesser degree, RET and fibroblast growth factor receptor kinases 1 to 4. In 2015, lenvatinib was approved by the US Food and Drug Administration (FDA) for the treatment of locally recurrent or metastatic, progressive DTC that no longer responds to radioiodine treatment [<a href="#rid10">10,18</a>]. The approved starting dose (used in the pivotal phase III trial) is 24 mg orally once daily.</p><p></p><p class="bulletIndent1">In an international, randomized, double-blind phase III trial, 392 patients with progressive, radioiodine refractory thyroid cancer were randomly assigned in a 2:1 ratio to <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> or placebo [<a href="#rid11">11</a>]. Tumor assessments for initial eligibility as well as serially while on therapy were performed centrally. The median progression-free survival (18.3 versus 3.6 months; hazard ratio [HR] for progression or death 0.21, 99% CI 0.14-0.31) and the response rate (64.8 versus 1.5 percent) were significantly better in the lenvatinib group. A similar response was seen in patients previously treated with another aaMKI, indicating benefit despite previous therapy. Compared with no complete responses in the placebo group, four patients (1.5 percent) in the lenvatinib group experienced durable complete responses. The median overall survival was not reached in either group. A preplanned subgroup analysis demonstrated that patients above the age of 65 years at the time of therapy initiation with lenvatinib had a significantly longer overall survival than those randomized to placebo (HR 0.53, 95% CI 0.31-0.91) [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1">In a randomized trial comparing the efficacy of two different starting doses of <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a>, the objective response rate at 24 weeks in patients who started 24 mg daily was 57 percent compared with 40 percent for those who started 18 mg daily (odds ratio 0.50, 95% CI 0.26-0.96), thus not meeting criteria for noninferiority of the two doses [<a href="#rid19">19</a>]. Despite differences in the starting doses, the rates of grade 3 or higher treatment-emergent adverse events were similar across the two arms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sorafenib</strong> – <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">Sorafenib</a> is an inhibitor of VEGFR 1, 2, and 3, platelet-derived growth factor receptor (PDGFR), common <em>RET/</em>PTC subtypes, c-kit, and less potently, <em>BRAF</em> [<a href="#rid20">20</a>]. In 2013, sorafenib was approved by the FDA for the treatment of locally recurrent or metastatic, progressive DTC that no longer responds to radioiodine treatment [<a href="#rid21">21</a>]. A typical starting dose of 400 mg orally twice daily is being used in selected patients with radiographically progressive metastatic papillary thyroid cancer for whom clinical trials are not available or appropriate; the efficacy of a lower starting dose has not been reported [<a href="#rid3">3,22</a>].</p><p></p><p class="bulletIndent1">In several small phase II trials, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> had beneficial effects on tumor progression in patients with DTC [<a href="#rid23">23-27</a>]. In a subsequent phase III trial, 417 patients with radioiodine-refractory DTC with locally advanced or metastatic disease that had radiographically progressed within 14 months of entry were randomized to either sorafenib or placebo [<a href="#rid12">12</a>]. Refractory disease was defined as at least one focus of tumor lacking radioiodine uptake, disease that had progressed within one year after radioiodine therapy, or cumulative treatment with at least 600 mCi of iodine 131 (131-I). Median progression-free survival was improved from 5.8 months on placebo to 10.8 with sorafenib (HR 0.59, 95% CI 0.45-0.76). Similar efficacy was seen across a wide variety of predefined subgroups. In a subsequent analysis, it was reported that the presence of a <em>BRAF</em> or <em>RAS</em> mutation was not predictive of response to treatment [<a href="#rid28">28</a>]. Although tumor responses were uncommon, six-month disease control rate was 54 percent. Toxicities led to dose modification in 78 percent of patients and permanent discontinuation of therapy in 19 percent. (See <a class="local">'Side effects shared by oral kinase inhibitors inhibiting VEGFR'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vandetanib</strong> – <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">Vandetanib</a> is an oral inhibitor that targets VEGFR, <em>RET/</em>PTC, and the epidermal growth factor receptor (EGFR). Vandetanib is available in the United States through a Risk Evaluation and Mitigation Strategy (REMS) program for the treatment of unresectable locally advanced or metastatic medullary thyroid cancer (see  <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">"Medullary thyroid cancer: Systemic therapy and immunotherapy", section on 'Vandetanib'</a>). Use outside of the indications defined in the REMS program is discouraged; however, given the strength of the data from a well-designed randomized trial [<a href="#rid13">13</a>], vandetanib may be a treatment option to consider for a patient with radioiodine-refractory, progressive papillary thyroid cancer for whom clinical trials, <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a>, and <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> are inappropriate. Given the low objective response rate, however, the drug is not likely to yield significant benefit for patients requiring major tumor shrinkage to palliate symptoms.</p><p></p><p class="bulletIndent1">In the randomized trial, 145 patients with locally advanced or metastatic DTC unresponsive to radioiodine were randomly assigned to <a class="drug drug_general" data-topicid="16484" href="/z/d/drug information/16484.html" rel="external">vandetanib</a> (300 mg once daily) or placebo [<a href="#rid13">13</a>]. After a median follow-up of approximately 19 months, fewer patients treated with vandetanib had disease progression (52 versus 61 patients in the placebo group [72 versus 84 percent]). Median progression-free survival was 11.1 and 5.9 months in the vandetanib and placebo groups, respectively (HR 0.63, 95% CI 0.54-0.74). There was no difference in objective partial response (8 percent of 72 and 5 percent of 73 patients, respectively) or overall survival (19 and 21 deaths, respectively). In subgroup analysis, efficacy may have been highest in patients with papillary thyroid cancer, and little difference in progression-free survival was suggested in patients with either follicular or poorly differentiated carcinomas. The most common adverse events resulting in discontinuation of vandetanib were prolongation of the QT interval and diarrhea. A larger, randomized, placebo-controlled phase III trial in patients with progressive, radioiodine-refractory DTC is underway.</p><p></p><p class="headingAnchor" id="H60680036"><span class="h3">Contraindications to aaMKI</span><span class="headingEndMark"> — </span>Relative contraindications to antiangiogenic multikinase inhibitors (aaMKIs) may include major surgery within 28 days, active bleeding, untreated hemorrhagic brain metastases, encasement by tumor of major arteries such as the carotid, or arterial thromboembolic event within the last 6 to 12 months. We also try to minimize use of potent antiangiogenic agents in patients with prior external beam radiotherapy (EBRT) to the neck due to reports of tracheoesophageal fistulas [<a href="#rid29">29</a>].</p><p>For patients with contraindications to aaMKIs, a BRAF inhibitor (eg, <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>) with or without an MEK inhibitor is an alternative. (See <a class="local">'Mutation-specific kinase inhibitor'</a> below.)</p><p class="headingAnchor" id="H3715063091"><span class="h2">Targetable mutation identified</span></p><p class="headingAnchor" id="H3944171597"><span class="h3">Mutation-specific kinase inhibitor</span><span class="headingEndMark"> — </span>If a targetable driver mutation is present (eg, <em>NTRK</em>, <em>ALK</em>, <em>RET</em>, <em>BRAF</em>), we suggest a mutation-specific kinase inhibitor (eg, an FDA-approved selective TRK or RET inhibitor, or use of a BRAF inhibitor) (<a class="graphic graphic_algorithm graphicRef130436" href="/z/d/graphic/130436.html" rel="external">algorithm 1</a>). Use of a BRAF inhibitor is typically reserved for patients with <em>BRAF</em> V600-mutant papillary thyroid cancer for whom aaMKI therapy might be contraindicated.</p><p>BRAF, RET, or TRK inhibitors frequently produce objective responses in DTC, though prolongation of progression-free survival has not yet been demonstrated in randomized trials. Of note, kinases that inhibit signaling along the mitogen-activated protein kinase (MAPK) pathway (eg, the BRAF inhibitors <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>) may allow re-expression of genes responsible for iodine metabolism in radioiodine-refractory DTC, thus permitting restoration of radioiodine uptake (also called "redifferentiation"). (See <a class="local">'Assessment for restoration of radioiodine uptake (redifferentiation)'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>TRK inhibition</strong> – Rearrangements of one of the neurotrophic tropomyosin receptor kinase (<em>NTRK</em>) genes leading to constitutive activation of signaling and tumor proliferation has been reported in a small percentage of patients with DTC [<a href="#rid30">30</a>]. <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">Larotrectinib</a> and <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>, highly selective inhibitors of TRK kinases, have been FDA approved for treatment of any solid tumor bearing an <em>NTRK</em>1-3 fusion mutation, including DTC. Of 15 patients with progressive radioiodine-refractory metastatic DTC bearing an <em>NTRK </em>rearrangement treated with larotrectinib across three clinical trials, 87 percent were reported to experience a partial response [<a href="#rid31">31-34</a>]. In an analysis of three phase I or II trials, one of five patients had a response with entrectinib [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/z/d/html/7743.html" rel="external">"Overview of the initial treatment of metastatic soft tissue sarcoma", section on 'NTRK gene fusion-positive tumors'</a>.)</p><p></p><p class="bulletIndent1">Restoration of radioiodine uptake has been reported with <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> [<a href="#rid36">36</a>]. (See <a class="local">'Assessment for restoration of radioiodine uptake (redifferentiation)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>RET inhibition</strong> – Rearrangements leading to <em>RET/</em>PTC oncogenes are the third most common driver mutations in papillary thyroid cancer, although they may be less commonly associated with advanced, radioiodine-refractory disease. Similar fusion abnormalities exist as well in non-small cell lung cancer along with other malignancies, leading to interest in development of selective RET kinase inhibitors.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">Selpercatinib</a> and <a class="drug drug_general" data-topicid="129470" href="/z/d/drug information/129470.html" rel="external">pralsetinib</a>, oral kinase inhibitors that selectively target RET kinase, are approved by the FDA for the treatment of advanced or metastatic <em>RET</em> fusion-positive thyroid cancer, <em>RET</em>-mutant medullary thyroid cancer, and other types of cancers that have an alteration (mutation or fusion) in the <em>RET</em> gene [<a href="#rid37">37,38</a>]. Of note, high response rates were seen with both selpercatinib and pralsetinib to treat medullary thyroid carcinoma with point mutations, but effectiveness may be less than reported for rearrangements in the <em>RET</em> gene. (See  <a class="medical medical_review" href="/z/d/html/2188.html" rel="external">"Medullary thyroid cancer: Systemic therapy and immunotherapy"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Selpercatinib</strong> – In the open-label LIBRETTO-001 trial of <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a> in 19 patients with previously treated, radioiodine-refractory, <em>RET</em> fusion-positive, non-medullary thyroid cancer, objective response (complete or partial) was reported in 79 percent [<a href="#rid39">39</a>]. The most common grade 3 or 4 adverse events included hypertension (21 percent), increased alanine aminotransferase (11 percent), increased aspartate aminotransferase (9 percent), hyponatremia (8 percent), and diarrhea (6 percent).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pralsetinib</strong> – In the open-label ARROW trial, in which nine patients with <em>RET-</em>fusion thyroid carcinoma were treated with <a class="drug drug_general" data-topicid="129470" href="/z/d/drug information/129470.html" rel="external">pralsetinib</a>, the overall response rate was 89 percent, all partial responses [<a href="#rid38">38,40-42</a>]. The most common grade 3 or 4 adverse events included hypertension (21 percent), fatigue (6 percent), diarrhea (5 percent), fever (2.2 percent), and dyspnea (2.2 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>BRAF inhibition</strong> – <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">Vemurafenib</a> and <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>, inhibitors of BRAF kinase, have been studied in patients with <em>BRAF-</em>mutated DTC. Dabrafenib in combination with <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> (a MEK inhibitor) has received regulatory approval for BRAF-mutated metastatic solid tumors, including papillary thyroid cancer; vemurafenib has not received this broader approval.</p><p></p><p class="bulletIndent1">These drugs can be considered for those patients with radiographically progressive, radioiodine-refracto<em>ry BRAF</em> V600-mutant papillary thyroid cancer for whom antiangiogenic therapy might be contraindicated or when a redifferentiation therapy strategy is employed. (See <a class="local">'Assessment for restoration of radioiodine uptake (redifferentiation)'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vemurafenib</strong> – In a phase II trial in which 51 patients with progressive radioiodine-refractory <em>BRAF</em> V600-mutant papillary thyroid cancer were treated with <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a>, the partial response rate was 38.5 percent, and median progression-free survival was 18.2 months in the anti-VEGFR-naïve group [<a href="#rid43">43</a>]. Less benefit was seen in the group previously treated with anti-VEGFR kinase inhibitors (27.3 percent and 8.9 months), but the study was not designed to compare formally the outcomes between the two arms. Common adverse events included rash, fatigue, weight loss, taste alteration, and alopecia; squamous cell carcinomas were identified in 22 percent of patients and noncutaneous squamous cell carcinomas in another 6 percent.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dabrafenib</strong> – In a multicenter, randomized phase II trial comparing <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> (150 mg twice daily) alone or in combination with the MEK inhibitor <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> (2 mg daily) in 53 patients wi<em>th BRAF-</em>mutant metastatic papillary thyroid cancer, objective response rates were similar, 50 and 54 percent, respectively [<a href="#rid44">44</a>]. Median progression-free survival and durations of response also did not differ between the two groups, and treatment-related adverse events were similar as well. Thus, the combination did not appear to have an advantage over single therapy with dabrafenib. Notably, the combination of dabrafenib and trametinib has been approved f<em>or BRAF-m</em>utated anaplastic thyroid carcinoma, and we have observed durable complete responses in patients wi<em>th BRAF-m</em>utated poorly differentiated thyroid carcinoma treated with both drugs as well [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/2189.html" rel="external">"Anaplastic thyroid cancer", section on 'BRAF V600E mutation identified'</a>.)</p><p></p><p class="bulletIndent1">Mutations <em>of BRAF</em> are associated with the greatest degree of MAPK activation and functional dedifferentiation. Restoration of radioiodine uptake has been demonstrated in small studies using either of the BRAF inhibitors, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> or <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a> [<a href="#rid45">45</a>]. (See <a class="local">'Assessment for restoration of radioiodine uptake (redifferentiation)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>PI3K inhibition</strong> – Both papillary and follicular carcinomas often develop mutations or upregulation of signaling through phosphoinositide 3-kinase (PI3K) as the disease progresses, leading to the suggestion that targeting this pathway may be of value. A phase II study of <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">everolimus</a> included 25 patients with progressive metastatic DTC who were treated with everolimus 10 mg daily [<a href="#rid46">46</a>]. Although the partial response rate was only 4 percent, median progression-free survival was 43 weeks. A second trial has also preliminarily reported efficacy from monotherapy with everolimus, as has a third with the combination of everolimus and <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a>; in these trials, particular efficacy was suggested in patients with metastatic Hürthle cell carcinoma [<a href="#rid47">47,48</a>]. Further investigation of the role of targeting this signaling pathway is expected. In patients whose tumors bear PI3K pathway mutations, we may add everolimus to <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> using starting doses approved for renal cell carcinoma (5 mg and 18 mg daily, respectively).</p><p></p><p class="headingAnchor" id="H3910093382"><span class="h1">EVALUATING RESPONSE TO TREATMENT</span></p><p class="headingAnchor" id="H673155318"><span class="h2">Imaging and assessment of adverse events</span></p><p class="bulletIndent1"><span class="glyph">●</span>While on therapy, we perform CT or MRI of known or suspected sites of disease every two to four months to determine how the disease is responding to therapy (ie, tumor burden).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients should also be assessed for potential treatment-related and disease-related complications. It is highly recommended that clinicians using these agents follow a comprehensive and standardized approach to assessment of adverse events during therapy, including careful documentation of the extent of baseline symptoms present prior to initiation of kinase inhibitors [<a href="#rid49">49</a>]. Subsequent management should include consideration of limited drug interruptions and dose modifications, carefully observing for balance of continued anti-tumor efficacy and reduced toxicity [<a href="#rid50">50</a>]. (See <a class="local">'Side effects shared by oral kinase inhibitors inhibiting VEGFR'</a> below.)</p><p></p><p class="headingAnchor" id="H3660709685"><span class="h2">Assessment for restoration of radioiodine uptake (redifferentiation)</span><span class="headingEndMark"> — </span>In patients treated with mitogen-activated protein kinase (MAPK) pathway inhibitors such as <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>, and <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a>, we may perform diagnostic radioiodine imaging after one to three months of therapy to determine if sufficient restoration of radioiodine uptake (redifferentiation) has occurred to permit subsequent radioiodine therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who have previously had significant radioiodine dosing, or with extensive pulmonary metastases, diagnostic radioiodine imaging with concurrent dosimetry may allow calculation of radioiodine activity for administration in order to minimize risk of subsequent pulmonary toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with a negative diagnostic radioiodine scan despite redifferentiation therapy, an empiric activity of 100 to 150 mCi may yet be considered.</p><p></p><p>Rearrangements of <em>RET</em> and <em>NTRK1</em> tyrosine kinases, activating mutations of <em>BRAF</em>, and activating mutations of<strong> </strong><em>RAS</em> are sequential components leading to activation of MAPK. Activation of MAPK promotes cell division and inhibits the sodium-iodide symporter (which usually facilitates iodine uptake) and thyroid peroxidase (facilitates organification). Mutations of <em>BRAF</em> are associated with the greatest degree of MAPK activation and functional dedifferentiation, followed by <em>RET</em> and <em>NTRK</em> fusions, and least by <em>RAS</em> mutations [<a href="#rid51">51</a>]. Thyroid cancers with these mutations are more likely to be refractory to radioiodine. (See  <a class="medical medical_review" href="/z/d/html/7819.html" rel="external">"Oncogenes and tumor suppressor genes in thyroid nodules and nonmedullary thyroid cancer"</a>.)</p><p>Inhibition of kinases signaling along the MAPK pathway may allow re-expression of genes responsible for iodine metabolism in radioiodine-refractory differentiated thyroid cancer (DTC), thus restoring sufficient radioiodine uptake to permit subsequent radioiodine therapy [<a href="#rid52">52-55</a>]. Restoration of radioiodine uptake has been demonstrated in small studies using either of the BRAF inhibitors, <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> or <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a>, as well as inhibitors of MEK [<a href="#rid45">45,56</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study involving 10 patients with radioiodine-refractory <em>BRAF</em> V600E mutated papillary thyroid cancer, six patients (60 percent) demonstrated new radioiodine uptake after nearly four weeks of therapy with <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a> (150 mg orally twice daily) [<a href="#rid45">45</a>]. Following radioiodine treatment with 150 mCi iodine 131 (131-I) in those six patients, two experienced partial response and four remained stable on imaging three months after therapy. <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">Vemurafenib</a> similarly restored radioiodine uptake and sensitivity, with selected tumor biopsies confirming increased thyroid-specific gene expression following effective MAPK pathway inhibition [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an interim analysis of results from another study in which 21 patients were evaluable after treatment with a combination of <a class="drug drug_general" data-topicid="89685" href="/z/d/drug information/89685.html" rel="external">trametinib</a> and <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>, partial response at six months was 38.1 percent with stable disease in 52.4 percent [<a href="#rid57">57</a>]. There were encouraging increases in radioiodine uptake and decreases in thyroglobulin levels (in the 15 of 21 patients who were antithyroglobulin antibody negative).</p><p></p><p><a class="drug drug_general" data-topicid="127843" href="/z/d/drug information/127843.html" rel="external">Selumetinib</a> is an investigational drug that selectively inhibits MEK 1 and MEK 2 (downstream effectors of MAPK pathway signaling) [<a href="#rid58">58</a>]. In a study of 20 patients with radioiodine-refractory papillary thyroid cancer, 12 patients (60 percent) had new and/or increased radioiodine uptake after treatment with selumetinib (75 mg orally twice daily for four weeks) [<a href="#rid55">55</a>]. In eight patients (40 percent), the absorbed radiation dose in the lesion was sufficient enough to continue selumetinib and receive a therapeutic dose of radioiodine. During six months of follow-up, there were partial responses in five patients and stable disease in three. Selumetinib was most effective in patients with <em>NRAS</em>-mutant thyroid cancers. There is an ongoing trial evaluating the role of selumetinib in augmenting radioiodine responsiveness in metastatic DTC that retains some iodine uptake on diagnostic imaging.</p><p><a class="drug drug_general" data-topicid="127843" href="/z/d/drug information/127843.html" rel="external">Selumetinib</a> has not been shown to improve the complete remission rate when administered with initial adjuvant radioiodine therapy in patients at high risk for recurrent disease after thyroidectomy [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H651486869"><span class="h1">REFRACTORY DISEASE OR KINASE INTOLERANCE</span><span class="headingEndMark"> — </span>Patients with refractory disease or with intolerance to one kinase inhibitor may benefit from treatment with another. Although cross-resistance has not been reported, likelihood of response is likely somewhat lower, however, with each successive regimen.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who cannot tolerate or who progress on first-line therapy with an antiangiogenic <strong>multikinase</strong> <strong>inhibitor</strong> (aaMKI), we discuss investigational agents, further attempts with other aaMKIs (eg, <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>), or (if appropriate) a BRAF inhibitor (eg, <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a> or <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>) or TRK or RET inhibitor (eg, <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> or <a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a>, respectively).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cabozantinib</strong><strong> </strong>– <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">Cabozantinib</a> is an inhibitor of several tyrosine kinases including VEGFR2, AXL, MET, and RET. In 2021, cabozantinib was approved by the FDA for the treatment of patients with locally recurrent or metastatic DTC that progresses following prior treatment with a VEGFR-targeted kinase inhibitor and that is refractory to radioiodine therapy [<a href="#rid60">60</a>]. Phase 1 and 2 studies have previously shown clinical activity of cabozantinib in patients with radioiodine-refractory DTC, including those previously treated with VEGFR-targeted therapy [<a href="#rid61">61,62</a>].</p><p></p><p class="bulletIndent2">In an interim analysis (median follow-up 6.2 months) of a double-blind, placebo-controlled, phase 3 trial of <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a> in 187 patients with previously treated, radioiodine-refractory differentiated thyroid cancer, cabozantinib improved progression-free survival [<a href="#rid63">63</a>]. In a subsequent report with extended follow-up (median 10.1 months), cabozantinib maintained the improvement in progression free survival (median 11 months versus 1.9 months with placebo [HR 0.22, 96% CI 0.15-0.32]) [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who cannot tolerate first-line therapy with a <strong>mutation-specific kinase inhibitor</strong>, we suggest an aaMKI such as <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> as the next-line option.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">Doxorubicin</a> or a taxane are alternatives for patients who are unable to tolerate or who fail several attempts at kinase inhibitor therapy. (See <a class="local">'Therapies infrequently used'</a> below.)</p><p></p><p class="headingAnchor" id="H9541759"><span class="h1">SIDE EFFECTS SHARED BY ORAL KINASE INHIBITORS INHIBITING VEGFR</span><span class="headingEndMark"> — </span>Side effects of vascular endothelial growth factor receptor (VEGFR)-targeted antiangiogenic multikinase inhibitors (aaMKIs) may include hypertension, renal toxicity, proteinuria, arthralgia/myalgia, headache, bleeding, myelosuppression, arterial thromboembolism, cardiotoxicity including prolonged QT intervals and risk for arrhythmia, thyroid dysfunction, cutaneous toxicity including hand-foot skin reaction, delayed wound healing, hepatotoxicity, nausea, vomiting, diarrhea, muscle wasting, fistula formation, osteonecrosis of the jaw, and reversible posterior leukoencephalopathy syndrome. TSH may become elevated during treatment, requiring an increase in the dose of thyroid hormone replacement or suppression therapy. Monitoring for and management of these side effects are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/86366.html" rel="external">"Non-cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/z/d/html/14250.html" rel="external">"Cardiovascular toxicities of molecularly targeted antiangiogenic agents"</a> and  <a class="medical medical_review" href="/z/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy"</a>.)</p><p class="headingAnchor" id="H3317664427"><span class="h1">THERAPIES INFREQUENTLY USED</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunotherapy</strong> – The use of agents that accentuate the capacity of a patient's own immune system to attack a malignant tumor has rapidly expanded in the past few years with the introduction of "checkpoint inhibitors." Drugs that block key cell-surface components on tumor cells or T lymphocytes, regulating the interaction between these two cell types, permit the immune system to recognize tumor-specific epitopes or neoantigens presented on the surface and thus allow immune targeting of these abnormal cells. In differentiated thyroid cancer (DTC), one trial evaluated the programmed cell death receptor 1 (PD-1) inhibitor <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a>, 10 mg/kg given intravenously every two weeks for 24 months or until progression or intolerable toxicity [<a href="#rid65">65</a>]. Of 22 patients with progressive metastatic disease and programmed cell death ligand 1 (PD-L1) expression in at least 1 percent of tumor or stroma cells, only two (9.1 percent) experienced a partial response and 54.5 percent had stable disease as their best overall response. The median progression-free survival rate was seven months. Adverse events were typical of those seen in other tumor types, including diarrhea, fatigue, and colitis.</p><p></p><p class="bulletIndent1">In a preliminary report from a phase II study, adding <a class="drug drug_general" data-topicid="96957" href="/z/d/drug information/96957.html" rel="external">pembrolizumab</a> to <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> as first-line therapy led to similar rates of partial response and stable disease as lenvatinib alone [<a href="#rid66">66</a>]. </p><p></p><p class="bulletIndent1">Low efficacy was reported from a phase II trial of the CTLA-4 inhibitor, <a class="drug drug_general" data-topicid="16084" href="/z/d/drug information/16084.html" rel="external">ipilimumab</a>, in combination with the PD-1 inhibitor, <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">nivolumab</a>, in 32 patients, with overall response rate of 9 percent and median progression-free survival 4.9 months [<a href="#rid67">67</a>]. Further clinical trials of checkpoint inhibitors in combination with targeted agents are underway.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cytotoxic agents</strong> – Although conventional cytotoxic agents are occasionally used for the treatment of patients with progressive symptomatic thyroid cancer that is unresponsive or not amenable to surgery, radioiodine therapy, or external radiotherapy, complete remission is rare, and long-term responses are uncommon. In addition, the availability of kinase inhibitors that induce durable responses or stability has changed the standard approach to treating patients with progressive metastatic disease, further limiting the role of cytotoxic agents [<a href="#rid7">7,8</a>]. (See <a class="local">'Initial systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">Doxorubicin</a> is the only cytotoxic agent approved by the US Food and Drug Administration (FDA) for metastatic thyroid cancer. Other single chemotherapeutic agents, including (but not limited to) <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a>, <a class="drug drug_general" data-topicid="9660" href="/z/d/drug information/9660.html" rel="external">mitoxantrone</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and aclarubicin, have not been shown to improve response rates. Similarly, combination therapy with doxorubicin and cisplatin has not been shown to improve the overall response compared with doxorubicin alone, and combination therapy may increase toxicity [<a href="#rid68">68,69</a>].</p><p></p><p class="bulletIndent1">Thus, we typically reserve conventional cytotoxic agents (eg, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>) for patients with metastatic refractory DTC who are unable to participate in clinical trials or who either cannot tolerate or fail antiangiogenic multikinase inhibitors (aaMKIs). <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">Cisplatin</a> or other agents may be considered in patients for whom doxorubicin is inappropriate (eg, those with pre-existing impaired cardiac function or myelosuppression). Data regarding combination regimens are even sparser than for single drugs. Such regimens may be appropriate in select patients.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Doxorubicin</strong> – In the initial studies with <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, 19 patients with metastatic papillary or follicular carcinoma were enrolled [<a href="#rid8">8,70</a>]. Partial responses (defined as &gt;50 percent reduction in tumor area on serial radiographs) to doxorubicin were seen in seven patients (37 percent), and stable disease was reported in another six. Pulmonary metastases appeared to be more likely to respond than bone metastases. By 1974, doxorubicin was considered the "drug of choice" for treating progressive, metastatic thyroid cancer [<a href="#rid71">71</a>]. Other studies of doxorubicin monotherapy have utilized varying definitions of response, but with similar results (30 to 40 percent partial response) [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent2">In a subsequent report of patients with documented progressive disease prior to chemotherapy, partial response (using World Health Organization [WHO] criteria) after six months of <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> treatment was seen in only 5 percent of patients, and stable disease between 1 and 22 months of duration was described in another 42 percent [<a href="#rid72">72</a>]. Response was significantly higher in those patients treated with 60 mg/m<sup>2</sup> every three weeks, compared with 15 mg/m<sup>2</sup> weekly. Overall, best responses occurred in patients with pulmonary metastases and high performance status.</p><p></p><p class="bulletIndent2">The recommended dose of <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> for monotherapy is 60 to 75 mg/m<sup>2</sup> every three weeks, administered as a continuous intravenous infusion for 48 to 72 hours to minimize the risk of cardiac toxicity. Cumulative doses of up to 600 mg/m<sup>2</sup> can be administered in responsive patients. Common adverse events can include granulocytopenia with accompanying infections, nausea, vomiting, and alopecia.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Taxanes</strong> – The use of taxanes in DTC is primarily based upon suggestion of efficacy in anaplastic carcinoma [<a href="#rid73">73</a>], rather than specific clinical trials. One report described three patients with metastatic DTC, all of whom had progressed despite radioiodine therapy [<a href="#rid74">74</a>]. Biweekly treatment with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> led to disease stabilization in all three, lasting 14 to 18 months, but no objective responses were described.</p><p></p><p class="headingAnchor" id="H1908808417"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113808.html" rel="external">"Society guideline links: Thyroid nodules and cancer"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to identifying patients</strong> <strong>for systemic therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients should be evaluated with comprehensive CT and/or MRI to establish the extent of disease and disease progression. Prior to therapy or in any patient with suspicious symptoms, imaging of the brain should be performed to rule out intracranial metastases that might require other forms of intervention first, such as surgery or radiation. (See <a class="local">'Patient selection for systemic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with asymptomatic metastatic tumors generally less than 1 to 2 cm in diameter and growing in diameter less than 20 percent per year can usually be <strong>monitored</strong> for disease progression (active surveillance). Known sites of metastatic disease should be imaged by CT or MRI every six months, and potential new sites of disease should be imaged every 12 to 24 months. (See <a class="local">'Patient selection for systemic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with metastatic, unresponsive tumors at least 1 to 2 cm in diameter and growing by at least 20 percent per year, or patients with symptoms related to multiple metastatic foci that cannot be alleviated with surgery or EBRT are candidates for <strong>systemic therapy</strong> (<a class="graphic graphic_algorithm graphicRef130436" href="/z/d/graphic/130436.html" rel="external">algorithm 1</a>). (See <a class="local">'Patient selection for systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles of initial systemic therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We prefer to administer systemic treatment in the context of a clinical trial. (Active clinical trials can be identified at: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fterm%3Dthyroid%2Bcancer%26recr%3DOpen&amp;token=RX0MbOaTp1kS6NCectJwzk2uEWpEWZoQPsdoKB16yZ3qpAUA9NDUrOsNaQ%2BcORTizx9RRRP%2B0nifSJG7uNrXvkV%2BLlyGRF5xkgeizFPzAO8%3D&amp;TOPIC_ID=2191" target="_blank">ClinicalTrials.gov</a>.) Increasingly, these options are dictated by the presence of specific gene mutations or signaling pathway abnormalities that are the targets of approved or investigational therapies. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients, who are unable to participate in clinical trials, the choice of initial kinase inhibitor depends on the result of somatic mutation testing, if available. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients whose disease burden, rate of tumor growth, or symptoms necessitate consideration of systemic therapy options, somatic mutation testing can be performed to identify oncogenic kinase abnormalities that might suggest specific treatment options that cannot be administered in the absence of mutational data (eg, gene rearrangements in <em>NTRK, ALK,</em> or <em>RET,</em> or point mutations in <em>BRAF</em>). Given the high cost of such testing and lack of coverage by many insurance providers, this option may not be realistic for many patients even if the lack of testing limits therapeutic options. (See <a class="local">'Initial systemic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selection of initial systemic therapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In the absence of a mutation, or if results are not available, we suggest <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> rather than another antiangiogenic multikinase inhibitor (aaMKI) (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Among the other aaMKIs, <a class="drug drug_general" data-topicid="10277" href="/z/d/drug information/10277.html" rel="external">sorafenib</a> is our next preferred option. (See <a class="local">'Targetable mutation not identified'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If tumor mutation results are available, we suggest a mutation-specific kinase inhibitor (eg, a RET, TRK, or BRAF inhibitor) if one of those mutations has been documented (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). BRAF inhibitors can be considered for those patients with radiographically progressive, radioiodine-refractory <em>BRAF</em> V600-mutant papillary thyroid cancer for whom antiangiogenic therapy might be contraindicated or if a redifferentiation approach is entertained. (See <a class="local">'Targetable mutation identified'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluating response to treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients require imaging (CT or MRI) of known or suspected sites of disease every two to four months to determine response to therapy. (See <a class="local">'Imaging and assessment of adverse events'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients should also be assessed for potential treatment- and disease-related complications. (See <a class="local">'Imaging and assessment of adverse events'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients being treated with a BRAF or other mitogen-activated protein kinase (MAPK)-pathway inhibitor may undergo diagnostic radioiodine imaging to determine if sufficient restoration of radioiodine uptake has occurred to permit subsequent radioiodine therapy. (See <a class="local">'Assessment for restoration of radioiodine uptake (redifferentiation)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Refractory disease</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who cannot tolerate or in whom initial therapy with an aaMKI fails, we discuss investigational agents, further attempts with other aaMKIs (eg, <a class="drug drug_general" data-topicid="87299" href="/z/d/drug information/87299.html" rel="external">cabozantinib</a>), or, if not done previously, somatic mutation testing to suggest mutation-specific treatment options, eg, a BRAF inhibitor (eg, <a class="drug drug_general" data-topicid="16798" href="/z/d/drug information/16798.html" rel="external">vemurafenib</a> or <a class="drug drug_general" data-topicid="89686" href="/z/d/drug information/89686.html" rel="external">dabrafenib</a>), a RET inhibitor (<a class="drug drug_general" data-topicid="128157" href="/z/d/drug information/128157.html" rel="external">selpercatinib</a>), or TRK inhibitor (eg, <a class="drug drug_general" data-topicid="119755" href="/z/d/drug information/119755.html" rel="external">larotrectinib</a> or <a class="drug drug_general" data-topicid="122336" href="/z/d/drug information/122336.html" rel="external">entrectinib</a>). (See <a class="local">'Refractory disease or kinase intolerance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who cannot tolerate or in whom initial therapy with a mutation-specific kinase inhibitor fails, an aaMKI such as <a class="drug drug_general" data-topicid="99962" href="/z/d/drug information/99962.html" rel="external">lenvatinib</a> is an alternative. (See <a class="local">'Targetable mutation identified'</a> above and <a class="local">'Refractory disease or kinase intolerance'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">Doxorubicin</a> is an alternative for patients who are unable to tolerate or who fail several attempts at kinase inhibitor therapy. (See <a class="local">'Refractory disease or kinase intolerance'</a> above and <a class="local">'Therapies infrequently used'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Brose MS, Smit JWA, Lin CC, et al. Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI). Thyroid 2022; 32:1059.</a></li><li><a class="nounderline abstract_t">Carhill AA, Litofsky DR, Ross DS, et al. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012. J Clin Endocrinol Metab 2015; 100:3270.</a></li><li><a class="nounderline abstract_t">Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26:1.</a></li><li><a class="nounderline abstract_t">Weitzman SP, Sherman SI. Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer. Endocrinol Metab Clin North Am 2019; 48:253.</a></li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on July 20, 2020).</li><li><a class="nounderline abstract_t">Brose MS, Worden FP, Newbold KL, et al. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. J Clin Oncol 2017; 35:2692.</a></li><li><a class="nounderline abstract_t">Bonadonna G, Monfardini S, De Lena M, et al. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 1970; 30:2572.</a></li><li><a class="nounderline abstract_t">Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 1974; 290:193.</a></li><li><a class="nounderline abstract_t">Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205.</a></li><li><a class="nounderline abstract_t">Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer 2015; 121:2749.</a></li><li><a class="nounderline abstract_t">Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015; 372:621.</a></li><li><a class="nounderline abstract_t">Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014; 384:319.</a></li><li><a class="nounderline abstract_t">Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012; 13:897.</a></li><li><a class="nounderline abstract_t">Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010; 11:962.</a></li><li><a class="nounderline abstract_t">Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol (Meeting Abstracts) 2008; 26.</a></li><li><a class="nounderline abstract_t">Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010; 16:5260.</a></li><li><a class="nounderline abstract_t">Ravaud A, de la Fouchardière C, Caron P, et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer 2017; 76:110.</a></li><li class="breakAll">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm434288.htm (Accessed on February 13, 2015).</li><li><a class="nounderline abstract_t">Brose MS, Panaseykin Y, Konda B, et al. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer. J Clin Endocrinol Metab 2022; 107:776.</a></li><li><a class="nounderline abstract_t">Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099.</a></li><li class="breakAll">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376443.htm (Accessed on December 02, 2013).</li><li class="breakAll">https://www.nccn.org/professionals/physician_gls/default.aspx.</li><li><a class="nounderline abstract_t">Brose MS, Troxel AB, Redlinger M, et al. Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients. J Clin Oncol (Meeting Abstracts) 2009; 27:6002.</a></li><li><a class="nounderline abstract_t">Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009; 27:1675.</a></li><li><a class="nounderline abstract_t">Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008; 26:4714.</a></li><li><a class="nounderline abstract_t">Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009; 161:923.</a></li><li><a class="nounderline abstract_t">Schneider TC, Abdulrahman RM, Corssmit EP, et al. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012; 167:643.</a></li><li class="breakAll">Brose MS, Nutting C, Shong  YK, et al. Association between tumor BRAF and RAS mutation status and clinical outcomes in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) randomized to sorafenib or placebo: sub-analysis of the phase III DECISION trial. ECCO/ESMO/ESTRO Annual Meeting; 2013; Amsterdam.</li><li><a class="nounderline abstract_t">Blevins DP, Dadu R, Hu M, et al. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 2014; 24:918.</a></li><li><a class="nounderline abstract_t">Prasad ML, Vyas M, Horne MJ, et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer 2016; 122:1097.</a></li><li><a class="nounderline abstract_t">Brose MS, Cabanillas ME, Cohen EEW, et al. Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions. Eur J Cancer 2017; 72:S148.</a></li><li><a class="nounderline abstract_t">Laetsch TW, DuBois SG, Mascarenhas L, et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 2018; 19:705.</a></li><li><a class="nounderline abstract_t">Drilon A, Laetsch TW, Kummar S, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 2018; 378:731.</a></li><li><a class="nounderline abstract_t">Tan DSW, Lassen UN, Albert CM, et al. Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach. Ann Oncol 2018; 29 Suppl 9:ix23.</a></li><li><a class="nounderline abstract_t">Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21:271.</a></li><li><a class="nounderline abstract_t">Groussin L, Clerc J, Huillard O. Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer. N Engl J Med 2020; 383:1686.</a></li><li class="breakAll">Selpercatinib capsules. United States Prescribing Information. US National Library of Medicine. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213246s000lbl.pdf (Accessed on May 11, 2020).</li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214701s000lbl.pdf (Accessed on December 04, 2020).</li><li><a class="nounderline abstract_t">Wirth LJ, Sherman E, Robinson B, et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med 2020; 383:825.</a></li><li><a class="nounderline abstract_t">BLU-667 Controls RET-Altered Thyroid Cancers. Cancer Discov 2019; 9:OF5.</a></li><li><a class="nounderline abstract_t">Hu M, Taylor M, Wirth LJ, et al. Clinical activity of selective RET inhibitor, BLU-667, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study. Thyroid 2018; 28:A170.</a></li><li><a class="nounderline abstract_t">Subbiah V, Hu MI, Gainor JF, et al. Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. J Clin Oncol 2020; 38:109.</a></li><li><a class="nounderline abstract_t">Brose MS, Cabanillas ME, Cohen EE, et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17:1272.</a></li><li><a class="nounderline abstract_t">Busaidy NL, Konda B, Wei L, et al. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. Thyroid 2022; 32:1184.</a></li><li><a class="nounderline abstract_t">Rothenberg SM, McFadden DG, Palmer EL, et al. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res 2015; 21:1028.</a></li><li><a class="nounderline abstract_t">Lim SM, Chang H, Yoon MJ, et al. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. Ann Oncol 2013; 24:3089.</a></li><li><a class="nounderline abstract_t">Lorch JH. A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC). J Clin Oncol 2013; 31 (suppl).</a></li><li><a class="nounderline abstract_t">Sherman E. Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer. J Clin Oncol 2013; 31 (suppl).</a></li><li><a class="nounderline abstract_t">Carhill AA, Cabanillas ME, Jimenez C, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab 2013; 98:31.</a></li><li><a class="nounderline abstract_t">Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. J Thyroid Res 2011; 2011:985780.</a></li><li><a class="nounderline abstract_t">Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med 2016; 375:1054.</a></li><li><a class="nounderline abstract_t">Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest 2011; 121:4700.</a></li><li><a class="nounderline abstract_t">Nagarajah J, Le M, Knauf JA, et al. Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin Invest 2016; 126:4119.</a></li><li><a class="nounderline abstract_t">Jaber T, Waguespack SG, Cabanillas ME, et al. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab 2018; 103:3698.</a></li><li><a class="nounderline abstract_t">Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013; 368:623.</a></li><li><a class="nounderline abstract_t">Dunn LA, Sherman EJ, Baxi SS, et al. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. J Clin Endocrinol Metab 2019; 104:1417.</a></li><li><a class="nounderline abstract_t">Leboulleux S, Do Cao C, Zerdoud S, et al. MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation. J Endocr Soc 2021; 5:A876.</a></li><li><a class="nounderline abstract_t">Hayes DN, Lucas AS, Tanvetyanon T, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res 2012; 18:2056.</a></li><li><a class="nounderline abstract_t">Ho AL, Dedecjus M, Wirth LJ, et al. Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). J Clin Oncol 2022; 40:1870.</a></li><li class="breakAll">FDA approves cabozantinib for differentiated thyroid cancer. US Food and Drug Administration. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-differentiated-thyroid-cancer (Accessed on February 13, 2023).</li><li><a class="nounderline abstract_t">Cabanillas ME, de Souza JA, Geyer S, et al. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. J Clin Oncol 2017; 35:3315.</a></li><li><a class="nounderline abstract_t">Brose MS, Shenoy S, Bhat N, et al. A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting. J Clin Oncol 2018; 36:6088.</a></li><li><a class="nounderline abstract_t">Brose MS, Robinson B, Sherman SI, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021; 22:1126.</a></li><li><a class="nounderline abstract_t">Brose MS, Robinson BG, Sherman SI, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial. Cancer 2022; 128:4203.</a></li><li><a class="nounderline abstract_t">Mehnert JM, Varga A, Brose MS, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer 2019; 19:196.</a></li><li><a class="nounderline abstract_t">Haugen B, French J, Worden FP, et al. Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial. J Clin Oncol 2020; 38:6512.</a></li><li><a class="nounderline abstract_t">Lorch JH, Barletta JA, NehsM, et al. A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC). J Clin Oncol 2020; 38:6513.</a></li><li><a class="nounderline abstract_t">Haugen BR. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999; 16:34.</a></li><li><a class="nounderline abstract_t">Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56:2155.</a></li><li class="breakAll">Burgess MA, Hill CS Jr. Chemotherapy in the management of thyroid cancer. In: Thyroid Cancer, Greenfield LD (Ed), CRC Press, W. Palm Beach, FL 1978. p.233.</li><li><a class="nounderline abstract_t">Carter SK, Blum RH. New chemotherapeutic agents--bleomycin and adriamycin. CA Cancer J Clin 1974; 24:322.</a></li><li><a class="nounderline abstract_t">Matuszczyk A, Petersenn S, Bockisch A, et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. Horm Metab Res 2008; 40:210.</a></li><li><a class="nounderline abstract_t">Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. Thyroid 2000; 10:587.</a></li><li><a class="nounderline abstract_t">Ikeda M, Tanaka K, Sonoo H, et al. [Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma]. Gan To Kagaku Ryoho 2007; 34:933.</a></li></ol></div><div id="topicVersionRevision">Topic 2191 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35950621" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26171797" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26462967" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30717907" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30717907" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28613956" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5474180" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Phase I and preliminary phase II evaluation of adriamycin (NSC 123127).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4808917" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10655437" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25913680" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25671254" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24768112" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22898678" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20851682" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Phase 2 study of sunitinib in refractory thyroid cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20847059" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28301826" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28301826" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34664662" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466206" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466206" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466206" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Effect of BRAFV600E on response to sorafenib in advanced thyroid cancer patients</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19255327" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Phase II trial of sorafenib in metastatic thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541894" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Phase II trial of sorafenib in advanced thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19773371" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22918300" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22918300" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24635127" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26784937" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29606586" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29466156" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32177963" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Larotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31838007" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33085869" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33085869" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33085869" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32846061" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31311839" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : BLU-667 Controls RET-Altered Thyroid Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical activity of selective RET inhibitor, BLU-667, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27460442" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35658604" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated Radioactive Iodine Refractory Differentiated Thyroid Cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25549723" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24050953" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Phase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23185034" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22007339" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27626519" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Biologic and Clinical Perspectives on Thyroid Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22105174" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27669459" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30032208" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23406027" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30256977" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : MERAIODE: A Redifferentiation Phase II Trial With Trametinib and Dabrafenib Followed by Radioactive Iodine Administration for Metastatic Radioactive Iodine Refractory Differentiated Thyroid Cancer Patients With a BRAFV600E Mutation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22241789" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35192411" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35192411" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28817373" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34237250" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36259380" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30832606" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Lenvatinib plus pembrolizumab combination therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC): Results of a multicenter phase II international thyroid oncology group trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9890738" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Management of the patient with progressive radioiodine non-responsive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3902203" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3902203" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4140753" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : New chemotherapeutic agents--bleomycin and adriamycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18348081" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10958311" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17565260" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : [Docetaxel administration for radioiodine-resistant patients with metastatic papillary thyroid carcinoma].</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
